Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 12, 2025 • 1:21 PM ET

Date/Time Source News Release
08/10/2023 04:30 PM EDT GlobeNewswire Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
08/01/2023 08:00 AM EDT GlobeNewswire Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
07/27/2023 08:10 AM EDT GlobeNewswire Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
07/05/2023 08:00 AM EDT GlobeNewswire Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
06/05/2023 08:00 AM EDT GlobeNewswire Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
05/25/2023 05:05 PM EDT GlobeNewswire Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
05/23/2023 01:20 PM EDT GlobeNewswire Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
04/27/2023 08:00 AM EDT GlobeNewswire Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
03/03/2023 08:00 AM EST GlobeNewswire Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
02/10/2023 07:00 AM EST GlobeNewswire Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
Page

Additional News

As of June 12, 2025 • 1:21 PM ET

Date/Time Source News Release
11/04/2022 09:21 AM EDT SeekingAlpha Ayala Pharmaceuticals GAAP EPS of -$0.66 misses by $0.17, revenue of $0.09M misses by $0.51M
11/04/2022 09:15 AM EDT Zacks Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Lags Revenue Estimates
10/20/2022 08:30 AM EDT ACCESSWIRE IA SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AERI, AYLA, HVBC
09/27/2022 08:47 AM EDT SeekingAlpha Ayala stock rises 12% on FDA fast track status for AL102 for desmoid tumors
09/14/2022 02:10 PM EDT Zacks Corcept (CORT) Up More Than 20% in Past 3 Months: Here's Why
09/13/2022 12:00 PM EDT Zacks Ayala Pharmaceuticals, Inc. (AYLA) Upgraded to Buy: Here's Why
09/12/2022 08:55 AM EDT SeekingAlpha Ayala Pharma rises on positive data from phase 2/3 trial of AL102 in desmoid tumors
09/08/2022 10:42 AM EDT Zacks Pacira (PCRX) Up on Data From Exparel Label Expansion Study
09/08/2022 07:24 AM EDT InvestorPlace Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
08/24/2022 12:00 AM EDT Channelchek Release - Ayala Pharmaceuticals Selected to Present Efficacy and Tolerability Data on AL102 in Desmoid Tumors at the European Society for Medical Oncology ESMO 2022 Congress
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.